Otros idiomas LAVA Therapeutics N.V.

Acciones

LVTX

NL0015000AG6

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 01/05/2024			Varia. Cinco días.	Varia. 1 de enero.
2,97 ^USD	+2,77 %		+8,39 %	+87,97 %

20/03	LAVA Therapeutics N.V. informa de los resultados de ganancias para el año completo finalizado el 31 de diciembre de 2023	CI
20/03	LAVA Therapeutics N.V. presenta los resultados del cuarto trimestre finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results	20/03
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results	20/03
LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)	05/03
LAVA Therapeutics N.V. Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052	05/03
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI	30/01
Sector Update: Health Care Stocks Softer Late Afternoon	25/01
Sector Update: Health Care Stocks Slipping Thursday Afternoon	25/01
Sector Update: Health Care	25/01
Lava Therapeutics to Study Gammabody Combined With Merck's Keytruda to Treat Metastatic Prostate Cancer	25/01
Upbeat US Economic Growth Data Lift Sentiment, Driving Premarket Gains for US Equity Futures	25/01
Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda	25/01
Top Premarket Gainers	25/01
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®	25/01
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc. to Evaluate LAVA-1207 in Combination with KEYTRUDA	25/01
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results	16/11
LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	06/09/23
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results	22/08/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas LAVA Therapeutics N.V.

Acciones

LVTX

NL0015000AG6

Otros idiomas

Filtros